JP MORGAN/CALL/MEDTRONIC/90/0.1/20.12.24 Stock

Warrant

DE000JT221X3

Market Closed - Börse Stuttgart 02:38:26 2024-07-02 am EDT
0.082 EUR -31.67% Intraday chart for JP MORGAN/CALL/MEDTRONIC/90/0.1/20.12.24
Current month-25.45%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-02 0.082 -31.67%
24-07-01 0.12 +9.09%
24-06-28 0.11 -15.38%
24-06-27 0.13 -7.14%
24-06-26 0.14 +7.69%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 02:38 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer J.P. Morgan
WKN JT221X
ISINDE000JT221X3
Date issued 2024-06-25
Strike 90 $
Maturity 2024-12-20 (171 Days)
Parity 10 : 1
Emission price 0.18
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.16
Lowest since issue 0.082
Spread 0.019
Spread %17.27%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
77.37 USD
Average target price
94.02 USD
Spread / Average Target
+21.53%
Consensus